The Aducanumab Aftermath: The Payer

<p>A controversial new $56,000 Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.</p><p><br></p><p>This episode is part of a special weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending.</p><p><br></p><p>Guest:</p><p><a href="https://www.arnoldventures.org/people/mark-e-miller-ph-d/" rel="noopener noreferrer" target="_blank">Mark Miller</a>, PhD, Executive Vice President for Health Care, Arnold Ventures</p><p><br></p><p>Explore the full series and additional resources:&nbsp;<a href="https://tradeoffs.org/aducanumab" rel="noopener noreferrer" target="_blank">https://tradeoffs.org/aducanumab</a></p><p><br></p><p>Read a transcript of this episode:&nbsp;<a href="https://tradeoffs.org/2021/06/24/the-aducanumab-aftermath-the-payer/" rel="noopener noreferrer" target="_blank">https://tradeoffs.org/2021/06/24/the-aducanumab-aftermath-the-payer/</a></p><p><br></p><p>Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: <a href="https://mailchi.mp/63a60bee39a5/tradeoffsnewsletter" rel="noopener noreferrer" target="_blank">bit.ly/tradeoffsnewsletter</a></p><p><br></p><p>Support this type of journalism today, with a gift: <a href="https://tradeoffs.org/donate" rel="noopener noreferrer" target="_blank">https://tradeoffs.org/donate</a></p><p><br></p><p>Follow us on Twitter:&nbsp;<a href="https://twitter.com/tradeoffspod" rel="noopener noreferrer" target="_blank">https://twitter.com/tradeoffspod</a></p> &#10;&nbsp;<br /><hr><p style='color: grey; font - size: 0.75em; '>See <a style='color: grey; ' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for privacy and opt-out information.</p>